Stephen D.  Chubb net worth and biography

Stephen Chubb Biography and Net Worth

Stephen D. Chubb is an Independent Director of Charles River Laboratories International Inc. He is a Special Limited Partner of Catalyst Healthcare Ventures, a venture investment firm specializing in medical devices and diagnostic products, since June 2010. From September 2010 through March 2011, Mr. Chubb served as President and Chief Executive Officer of Allegro Diagnostics, Inc., a privately held molecular diagnostics company focused on the development and future sale of innovative genomic tests for the diagnosis, staging, and guided treatment of lung cancer and lung diseases. Mr. Chubb was previously Chairman and Chief Executive Officer of Matritech, Inc., a publicly traded leading developer of proteomics-based diagnostic products for the early detection of cancer, from its inception in 1987 until December 2007. Mr. Chubb served as President and Chief Executive Officer of T Cell Sciences, Inc. and as President and Chief Executive Officer of Cytogen Corp., both publicly traded biotechnology companies. Mr. Chubb also previously served as Chairman of the Board of Trustees of Mount Auburn Hospital in Cambridge, Massachusetts and as a director of Caregroup Healthcare System, and currently serves as a director of Amylyx Pharmaceuticals Inc. Mr. Chubb has been a director since 1994. Mr. Chubb brings to the Board a wealth of industry and business expertise, drawing upon his 30-year history as a Chief Executive Officer, president and board member at a variety of public and private life sciences companies. The Board benefits particularly from Mr. Chubb's strong biotechnology industry expertise, and he also brings a valued perspective given his service to hospitals and healthcare providers. In addition, as a result of his background as a Certified Public Accountant and prior service as a public company Chief Financial Officer, Mr. Chubb qualifies as an "audit committee financial expert" under SEC guidelines.

What is Stephen D. Chubb's net worth?

The estimated net worth of Stephen D. Chubb is at least $7.61 million as of February 19th, 2019. Mr. Chubb owns 38,868 shares of Charles River Laboratories International stock worth more than $7,609,188 as of November 23rd. This net worth estimate does not reflect any other assets that Mr. Chubb may own. Learn More about Stephen D. Chubb's net worth.

How do I contact Stephen D. Chubb?

The corporate mailing address for Mr. Chubb and other Charles River Laboratories International executives is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. Charles River Laboratories International can also be reached via phone at (781) 222-6000 and via email at [email protected]. Learn More on Stephen D. Chubb's contact information.

Has Stephen D. Chubb been buying or selling shares of Charles River Laboratories International?

Stephen D. Chubb has not been actively trading shares of Charles River Laboratories International during the past quarter. Most recently, Stephen D. Chubb sold 1,000 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $217.65, for a transaction totalling $217,650.00. Learn More on Stephen D. Chubb's trading history.

Who are Charles River Laboratories International's active insiders?

Charles River Laboratories International's insider roster includes William Barbo (VP), Robert Bertolini (Director), Stephen Chubb (Director), Victoria Creamer (EVP), James Foster (CEO), Birgit Girshick (VP), Michael Knell (CAO), Deborah Kochevar (Director), Joseph LaPlume (EVP), George Massaro (Director), Shannon Parisotto (EVP), David Smith (CFO), and Richard Wallman (Director). Learn More on Charles River Laboratories International's active insiders.

Are insiders buying or selling shares of Charles River Laboratories International?

During the last year, insiders at the medical research company sold shares 5 times. They sold a total of 22,857 shares worth more than $5,420,562.80. The most recent insider tranaction occured on November, 7th when Director Richard F Wallman sold 6,621 shares worth more than $1,430,930.52. Insiders at Charles River Laboratories International own 1.3% of the company. Learn More about insider trades at Charles River Laboratories International.

Information on this page was last updated on 11/7/2024.

Stephen D. Chubb Insider Trading History at Charles River Laboratories International

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2020Sell1,000$217.65$217,650.00
2/19/2019Sell4,540$141.23$641,184.2038,868View SEC Filing Icon  
2/15/2018Sell2,872$108.70$312,186.4036,461View SEC Filing Icon  
12/2/2016Sell4,564$71.57$326,645.4830,849View SEC Filing Icon  
2/1/2016Sell2,000$74.76$149,520.0011,504View SEC Filing Icon  
11/2/2015Sell2,000$66.57$133,140.0013,504View SEC Filing Icon  
3/3/2015Sell2,000$75.52$151,040.00View SEC Filing Icon  
2/18/2015Sell5,011$73.97$370,663.67View SEC Filing Icon  
12/1/2014Sell2,000$64.44$128,880.00View SEC Filing Icon  
9/2/2014Sell2,000$59.18$118,360.00View SEC Filing Icon  
6/2/2014Sell2,000$52.93$105,860.00View SEC Filing Icon  
See Full Table

Stephen D. Chubb Buying and Selling Activity at Charles River Laboratories International

This chart shows Stephen D Chubb's buying and selling at Charles River Laboratories International by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Charles River Laboratories International Company Overview

Charles River Laboratories International logo
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $195.77
Low: $193.26
High: $198.18

50 Day Range

MA: $194.99
Low: $178.58
High: $220.69

2 Week Range

Now: $195.77
Low: $176.48
High: $275.00

Volume

575,717 shs

Average Volume

863,318 shs

Market Capitalization

$10.01 billion

P/E Ratio

24.50

Dividend Yield

N/A

Beta

1.38